
CLAIMS

1. A compound of Formula (II):



(II),

or a pharmaceutically acceptable salt thereof, wherein:

R^1 is halo or methoxy;

R^6 is hydrogen or halo;

p is 0;

R^4 is

a) 3- to 6-membered heterocycloalkyl or heterocycloalkenyl comprising exactly two annular heteroatoms, both of which are nitrogen atoms, wherein the 3- to 6-membered heterocycloalkyl or heterocycloalkenyl is substituted with one or more independently selected $–C_1$-C_6 alkyl substituents and is optionally further substituted with one or more oxo substituents,

b) 3- to 6-membered heterocycloalkyl or heterocycloalkenyl comprising exactly one annular heteroatom, which is an oxygen atom, wherein the 3- to 6-membered heterocycloalkyl or heterocycloalkenyl is optionally substituted with one or more independently selected oxo or $–C_1$-C_6 alkyl substituents,

c) 3- to 6-membered heterocycloalkyl or heterocycloalkenyl substituted with one or more independently selected -$S(O)_2$-C_1-C_6alkyl substituents and optionally further substituted with one or more independently selected oxo or $–C_1$-C_6 alkyl substituents,



d) 5-membered heterocycloalkyl or heterocycloalkenyl comprising exactly two annular heteroatoms, one of which is a nitrogen atom and the other of which is an oxygen atom, wherein the 5-membered heterocycloalkyl or heterocycloalkenyl is optionally substituted with one or more independently selected oxo, C_1-C_6 alkyl, or -$S(O)_2$-(C_1-C_6 alkyl) substituents,


e) 6-membered heterocycloalkyl or heterocycloalkenyl comprising exactly two annular heteroatoms, one of which is a sulfur atom and the other of which is a nitrogen atom, wherein

the 6-membered heterocycloalkyl or heterocycloalkenyl is optionally substituted with one or more independently selected oxo, C_1-C_6 alkyl, or -$S(O)_2$-(C_1-C_6 alkyl) substituents,

f) 5-membered heteroaryl comprising exactly two annular heteroatoms, one of which is a nitrogen atom and the other of which is an oxygen atom, wherein the 5-membered heteroaryl is substituted with exactly one methyl substituent,

g) 5-membered heteroaryl comprising exactly two annular heteroatoms, both of which are nitrogen atoms, wherein the 5-membered heteroaryl is substituted with one or more methyl substituents,




h) 6-membered heteroaryl comprising one or two annular heteroatoms and optionally substituted with one or more methyl substituents, wherein the 6-membered heteroaryl is other than  or , or

i) ;

and

R^5 is hydrogen;

provided that for the compound of formula (II),

R^4 is other than 4-methylpiperazinyl, 4-phenylpiperazinyl, 4-pyridylpiperazinyl, 4-(furanylmethyl)piperazinyl, , , and .

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^1 is halo.

3. The compound of claim 1 or claim 2, or a pharmaceutically acceptable salt thereof, wherein R^1 is Cl or F.

4. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^1 is methoxy.

5. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt thereof, wherein R^4 is selected from the group consisting of:










3- to 6-membered heterocycloalkyl or heterocycloalkenyl comprising exactly two annular heteroatoms, both of which are nitrogen atoms, wherein the 3- to 6-membered heterocycloalkyl or heterocycloalkenyl is substituted with one or more independently selected $–C_1$-C_6 alkyl substituents and is optionally further substituted with one or more oxo substituents,



3- to 6-membered heterocycloalkyl or heterocycloalkenyl comprising exactly one annular heteroatom, which is an oxygen atom, wherein the 3- to 6-membered heterocycloalkyl or heterocycloalkenyl is optionally substituted with one or more independently selected oxo or $–C_1$-C_6 alkyl substituents,

3- to 6-membered heterocycloalkyl or heterocycloalkenyl substituted with one or more independently selected -$S(O)_2$-C_1-C_6alkyl substituents and optionally further substituted with one or more independently selected oxo or $–C_1$-C_6 alkyl substituents,

5-membered heterocycloalkyl or heterocycloalkenyl comprising exactly two annular heteroatoms, one of which is a nitrogen atom and the other of which is an oxygen atom, wherein the 5-membered heterocycloalkyl or heterocycloalkenyl is optionally substituted with one or more independently selected oxo, $–C_1$-C_6 alkyl, or -$S(O)_2$-(C_1-C_6 alkyl) substituents, and

6-membered heterocycloalkyl or heterocycloalkenyl comprising exactly two annular heteroatoms, one of which is a sulfur atom and the other of which is a nitrogen atom, wherein the 6-membered heterocycloalkyl or heterocycloalkenyl is optionally substituted with one or more independently selected oxo, $–C_1$-C_6 alkyl, or -$S(O)_2$-(C_1-C_6 alkyl) substituents.

6. The compound of any one of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein R^4 is selected from the group consisting of , , , , , , , , ,





, and 
.

7. The compound of any one of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein R^4 is

3- to 6-membered heterocycloalkyl or heterocycloalkenyl comprising exactly two annular heteroatoms, both of which are nitrogen atoms, wherein the 3- to 6-membered heterocycloalkyl or heterocycloalkenyl is substituted with one or more independently selected –C_1-C_6 alkyl substituents and is optionally further substituted with one or more oxo substituents, or

6-membered heterocycloalkyl or heterocycloalkenyl comprising exactly two annular heteroatoms, one of which is a sulfur atom and the other of which is a nitrogen atom, wherein the 6-membered heterocycloalkyl or heterocycloalkenyl is optionally substituted with one or more independently selected oxo, –C_1-C_6 alkyl, or -S(O)$_2$-(C_1-C_6 alkyl) substituents.

8. The compound of any one of claims 1-5 and 7, or a pharmaceutically acceptable salt thereof, wherein R^4 is 3- to 6-membered heterocycloalkyl or heterocycloalkenyl comprising exactly two annular heteroatoms, both of which are nitrogen atoms, wherein the 3- to 6-membered heterocycloalkyl or heterocycloalkenyl is substituted with one or more independently selected –C_1-C_6 alkyl substituents and is further substituted with one or more oxo substituents.



9. The compound of any one of claims 1-5 and 7, or a pharmaceutically acceptable salt thereof, wherein R^4 is 
, 
, or 
.




10. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt thereof, wherein R4 is 5-membered heterocycloalkyl or heterocycloalkenyl comprising exactly two annular heteroatoms, one of which is a nitrogen atom and the other of which is an oxygen atom, wherein the 5-membered heterocycloalkyl or heterocycloalkenyl is optionally substituted with one or more independently selected –C1-C6 alkyl, or -S(O)2-(C1-C6 alkyl) substituents.


11. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt thereof, wherein R^4 is selected from the group consisting of:

5-membered heteroaryl comprising exactly two annular heteroatoms, one of which is a nitrogen atom and the other of which is an oxygen atom, wherein the 5-membered heteroaryl is substituted with exactly one methyl substituent,

5-membered heteroaryl comprising exactly two annular heteroatoms, both of which are nitrogen atoms, wherein the 5-membered heteroaryl is substituted with one or more methyl substituents, and







6-membered heteroaryl comprising one or two annular heteroatoms and optionally substituted with one or more methyl substituents, wherein the 6-membered heteroaryl is other than  or .








12. The compound of any one of claims 1-4 and 11, or a pharmaceutically acceptable salt thereof, wherein R^4 is selected from the group consisting of , , and .








13. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt thereof, wherein R^4 is .








14. A compound selected from the group consisting of





Compound No.	**Structure**

392	 ,
393	 ,
396	 ,
397	 ,
398	 ,
399	 ,


400	 ,
403	 ,
407	 ,
412	 ,
413	 ,
435	 ,
440	 ,


460	 ,
495	 ,
503	 ,
504	 ,
507	 ,
508	 ,
538	 ,


539	 ,
540	 ,
541	 ,
542	
543	
544	
545	

549	
550	
551	
552	

or a pharmaceutically acceptable salt thereof.

15. The compound of claim 14, or a pharmaceutically acceptable salt thereof, wherein the compound is .

16. The compound of claim 14, or a pharmaceutically acceptable salt thereof, wherein the compound is .

17. The compound of claim 14, or a pharmaceutically acceptable salt thereof, wherein the compound is .

18. A pharmaceutical composition comprising a compound according to any one of claims 1-17, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

19. Use of a compound of any one of claims 1-17, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 18, in the manufacture of a medicament for treating a disease or condition mediated by NAMPT activity, wherein the disease or condition is selected from the group consisting of cancer, a hyperproliferative disease or condition, an inflammatory disease or condition, a metabolic disorder, a cardiac disease or condition, heart failure, heart failure with preserved ejection fraction, chemotherapy induced tissue damage, a renal disease, a metabolic disease, a neurological disease or injury, a neurodegenerative disorder or disease, diseases caused by impaired stem cell function, diseases caused by DNA damage, primary mitochondrial disorders, a muscle disease or muscle wasting disorder, obesity, atherosclerosis, insulin resistance, type 2 diabetes, cardiovascular disease, Alzheimer’s disease, Huntington’s disease, Parkinson's disease, amyotrophic lateral sclerosis, depression, Down syndrome, neonatal nerve injury, aging, axonal degeneration, carpal tunnel syndrome, Guillain-Barre syndrome, nerve damage, polio (poliomyelitis), and spinal cord injury.

20. A compound of any one of claims 1-17, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 18, for use in therapy.